Safety and selective: Tricyclic antidepressant vs. selective serotonin reuptake inhibitors

Acta Psychiatrica Scandinavica, Supplement

Volumn 101, Issue 403, 2000, Pages 17-25

  Peretti, S ^a   Judge, R ^b   Hindmarch, I ^c  

^a Psychiatre Chef de Service   (France)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Antidepressant; Compliance; Discontinuation; SSRI; TCA

Indexed keywords

AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; FLUOXETINE; FLUVOXAMINE; LOFEPRAMINE; MOCLOBEMIDE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; AGITATION; ANXIETY; BODY WEIGHT; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; CONSTIPATION; DEATH; DEPRESSION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; INSOMNIA; MALAISE; META ANALYSIS; NAUSEA; PSYCHOPHARMACOLOGY; SEXUAL DYSFUNCTION; TREMOR; VERTIGO; VISUAL DISORDER; VOMITING; XEROSTOMIA; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG TOLERANCE; REVIEW;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; CLINICAL TRIALS; COGNITION DISORDERS; DRUG TOLERANCE; HUMANS; META-ANALYSIS; SEROTONIN UPTAKE INHIBITORS;

EID: 0034564477     PISSN: 00651591     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (66)

1. Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors
2. Synaptic pharmacology of antidepressants: An update
3. Treating comorbid depression and anxiety
4. Evolutionary trends in the pharmacotherapeutic management of depression
5. Anxiety symptom relief in depression treatment outcomes
6. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
7. Fluvoxamine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
8. Paroxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness
9. Selective serotonin reuptake inhibitors
10. Prescription-event monitoring of 10,401 patients treated with fluvoxamine
11. Double-blind comparison of bupropion and fluoxetine in depressed outpatients
12. Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors
13. Sertraline. A review of its pharmacodynamic and phannacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder
14. Diagnostic dilemmas presented by patients with anxiety and depression
15. Fluoxetine-induced sexual dysfunction
16. The role of serotonin in sexual dysfunction: Fluoxetine-associated orgasm dysfunction
17. Clinical overview of serotonin reuptake inhibitors
18. Changes in adverse events reported by patients during six months of fluoxetine therapy
19. Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder
20. Adverse events and treatment discontinuations in fluoxetine clinical trials
21. Fluoxetine: Relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression
22. Citalopram in depression - Meta-analysis of intended and unintended effects
23. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: A meta-analysis
24. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis
25. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
26. SSRIS versus tricyclic antidepressants in depressed in-patients: A meta-analysis of efficacy and tolerability
27. The efficacy of selective serotonin re-uptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants
28. Therapeutic potentials of recently introduced antidepressants
29. Comparative behavioural toxicity of the selective serotonin reuptake inhibitors
30. Behavioural toxicity and depression: The search for optimum therapy
31. Critical flicker fusion threshold and anticholinergic effects of chronic antidepressant treatment in remitted depressives
32. Effects of fluoxetine and dothiepin on cognition and sleep in depressed patients
33. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers
34. Effects of antidepressants on cardiac function
35. The cardiovascular effects of antidepressants
36. Effect of fluoxetine on the electrocardiogram
37. The electrocardiogram as a tool for therapeutic monitoring: A critical analysis
38. Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine
39. Comparative effects of fluoxetine and amitriptyline on cardiac function
40. Cardiovascular effects of fluoxetine in depressed patients with heart disease
41. The safety of antidepressants
42. Antidepressant medications and the relative risk of suicide attempt and suicide
43. Relative mortality from overdose of antidepressants
44. Fluoxetine versus tricyclic antidepressants: A prospective multicenter study of antidepressant drug overdoses
45. Outpatient utilization of antidepressants: A prescription database analysis
46. The treatment of depression: Prescribing patterns of antidepressants in primary care in the UK
47. Fatal overdose with citalopram
48. Citalopram toxicity [letter]
49. Selective serotonin reuptake inhibitors: Pharmacologic profiles and potential therapeutic distinctions
50. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients
51. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression
52. A double blind comparison of paroxetine and fluoxetine in patients with major depression
53. A double-blind, comparative study of paroxetine and fluoxetine in out-patients with depression
54. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression
55. Double-blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
56. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression
57. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression
58. Citalopram versus fluoxetine: A double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice
59. Comparative safety and tolerability of selective serotonin reuptake inhibitors
60. Effects of SSRIs on sexual function: A critical review
61. Selective serotonin reuptake inhibitors: Meta-analysis of discontinuation rates
62. Changes in weight during a 1-year trial of fluoxetine
63. Phasic craving for carbohydrate observed with citalopram
64. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies
65. Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine